Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, …) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.
Looking for a particular Physiogenex employee's phone or email?
The Physiogenex annual revenue was $5 million in 2026.
François Briand is the Director - Research and Business Development of Physiogenex.
23 people are employed at Physiogenex.
Physiogenex is based in Escalquens, Occitania.
The NAICS codes for Physiogenex are [5417, 541, 541713, 54171, 54].
The SIC codes for Physiogenex are [87, 873].